Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

Spinal Cord Research Heads New Funding in London

Release issued 7th May 2008

THE UNIVERSITY OF WESTERN ONTARIO - MEDIA RELEASE
FOR IMMEDIATE RELEASE

May 7, 2008

SPINAL CORD RESEARCH HEADS NEW FUNDING IN LONDON:
More Than $10 Million for Leading Health Research at City Institutions

LONDON, ON – A researcher striving to help patients recover from spinal cord injuries headlines an announcement of more than $10.5 million in funding from the Canadian Institutes of Health Research (CIHR) at The University of Western Ontario and Lawson Health Research Institute today.

Scientists believe a lack of cell regeneration after spinal cord injuries can be attributed to the molecular makeup of scar tissue that inhibits nerve growth. Dr. Arthur Brown, a scientist at Robarts Research Institute at Western, received $782,455 from CIHR to study a protein he has identified that ma ycontrol regeneration in the injured spinal cord. Currently, there are no effective treatments for spinal cord injuries.

Astrocytes – the major cell type that produces scars in the injured central nervous system – receive a variety of signals after injury and respond by producing scar proteins, including some that inhibit regeneration and others that promote it. Brown’s group has discovered that a protein called SOX9 promotes the expression of anti-regenerative scar genes and reduces the expression of pro-regenerative ones. This makes SOX9 inhibition a very attractive strategy to encourage regeneration. He hopes to further understand how SOX9 works with other proteins to regulate scar gene expression and to test whether SOX9 inhibition improves regeneration after spinal cord injuries.

With more than 12,000 spinal cord injuries in Canada and the United States annually, these injuries affect not only patients on a personal level, but also the health care system. Approximately 275,000 North Americans live with permanent, serious disabilities due to spinal cord injuries.

“It has been estimated that the impact of neurotrauma is one of the single most costly occurrences in Ontario’s health system,” saysBrown. “Improving recovery and regeneration after spinal cord injuries will relieve pressure on our healthcare system and, more importantly, produce priceless improvements to the quality of life of these patients.”

“London has developed a stellar reputation for health research and we’re grateful to the CIHR for their continued support of health-related initiatives across disciplines throughout the city, ”says Ted Hewitt, Western’s Vice-President (Research & International Relations).

“We are proud of the work of all recipients and CIHR’s support of our many local researchers is critical in helping us to make a difference in the lives of patients,” says Dr. David Hill, Lawson’s Scientific Director.

In this round of funding, 24 projects at Western and Lawson received $10,585,000 for research in a variety of fields, including mental health, prenatal care, organ donation and research ethics. For more information, please visit: www.cihr-irsc.gc.ca

– 30 –

Contact:
Arthur Brown, Robarts Research Institute, 519-663-5777 x33932, abrown@robarts.ca

Douglas Keddy, Research Communications Coordinator, Western, 519-661-2111 ext. 87485, dkeddy@uwo.ca

Company details

If you want to find out more about the company visit The University of Western Ontario - Industry Liaison profile.

Latest The University of Western Ontario - Industry Liaison press releases

Small trial ad
Yissum Technology Transfer Hebrew University
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us